AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 11 min read$UTHR

ROTHBLATT MARTINE A sold $4.9M of UTHR (indirect holdings)

ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $511.09 ($507.84–$514.96, $4.86M total) across 8 trades on 2026-08-31 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · ROTHBLATT MARTINE A
Published Sep 1, 2026, 8:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 1, 2026, 8:54 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$UTHR
Bearish
medium confidence
Mentioned
$UTHR
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$UTHRBearishLow
01

Why it matters

The CEO’s sale reduces her ownership but follows a pre‑arranged plan, suggesting limited new information for the market.

02

Market read

Insider sale provides modest new data for traders; likely limited price effect.

03

What to watch

Potential upcoming clinical data releases or partnership announcements could offset the sale’s impact.

Relevance 5/10Novelty 5/10Timing: post‑market 2026‑08‑31

Background

Form 4 filing discloses insider transactions; such filings are primary sources for insider activity.

Company-level read

Ticker impact

$UTHRBearishMedium confidence
Context

CEO Martine A. Rothblatt sold 9,500 shares for $4.9M via a 10b5‑1 plan, reducing her stake to 324,443 shares.

Expected impact

Modest downward pressure on UTHR price in the next few days.

Evidence & confidence

The sale size ($4.9M) is material for a mid‑cap biotech, but the insider used a pre‑arranged plan, limiting informational content.

Market effects

Sector

May prompt analysts to reassess insider sentiment in the biotech/therapeutics sector.

Regional

Limited to U.S. biotech investors; no broader regional effect.

Global

Minimal global impact beyond UTHR shareholders.

Counterpoint

What could challenge this read

The sale was pre‑arranged under a 10b5‑1 plan, so it may not reflect negative outlook; price could remain stable.

Key entities

  • Company
    United Therapeutics Corp

    Biopharmaceutical company developing therapies for pulmonary arterial hypertension and other conditions.

  • Executive
    Martine A. Rothblatt

    Chairperson & CEO of United Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

UTHR insider trading history →

Related articles

OCT 28
$UTHRMed

United Therapeutics Receives FDA Clearance to Begin Clinical Trial of Inhaled PAH Treatment

United Therapeutics (UTHR) received FDA clearance to start clinical trials for Treprostinil-Iloprost SMI, an inhaled treatment for pulmonary arterial hypertension (PAH). The phase 1 trial will assess safety and tolerability. The therapy aims to address symptom flare-ups between maintenance doses. UTHR plans a phase 2 trial in 2027 if initial results are positive. PAH affects around 500,000 people globally.

finance.yahoo.com2 min
OCT 28
$UTHRMed

FDA clears a trial of a two-drug inhaler that could be the first as-needed therapy for lung artery disease.

The FDA approved a trial for Treprostinil-Iloprost SMI, a potential first as-needed inhaler therapy for pulmonary arterial hypertension (PAH). United Therapeutics plans a phase 1 study in 2026, with a phase 2 study in PAH patients anticipated in 2027. The therapy combines treprostinil and iloprost, aiming to provide episodic symptom relief. United Therapeutics aims to expand its PAH treatment portfolio.

stocktitan.net2 min